Endo Reports Third Quarter, Ups 2021 Financial Guidance

 Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021.

"We delivered strong third-quarter results driven by outstanding execution across all of our businesses. As a result of our year-to-date performance and our expectations for the remainder of 2021, we are raising our full-year 2021 financial guidance," said Blaise Coleman, President and Chief Executive Officer at Endo. "Additionally, we are pleased with our progress against our strategic priorities including our efforts to expand and enhance our portfolio with the recent launch of varenicline tablets, the only available FDA approved generic version of Chantix®, and the continued positive market response to QWO®."

2021 FINANCIAL GUIDANCE

Endo is updating its financial guidance for the full-year ending December 31, 2021 by raising the expected ranges regarding revenues, adjusted diluted net income per share from continuing operations and adjusted EBITDA. The guidance below contemplates a range of potential outcomes that reflect uncertainties in certain key assumptions including, among other things, uncertainties related to the COVID-19 pandemic. These statements are forward-looking, and actual results may differ materially from Endo's expectations, as further discussed below under the heading "Cautionary Note Regarding Forward-Looking Statements."

	Full-Year 2021
	Prior		Current
Total Revenues, Net	$2.73B - $2.79B		$2.90B - $2.94B
Adjusted EBITDA	$1.23B - $1.28B		$1.40B - $1.42B
Adjusted Diluted Net Income per Share from Continuing Operations	$2.15 - $2.30		$2.80 - $2.85
Assumptions:
Adjusted Gross Margin	~70.0% - 71.0%		~71.5%
Adjusted Operating Expenses as a Percentage of Total Revenues, Net	~28.5%		~26.5%
Adjusted Interest Expense	~$560M		~$560M
Adjusted Effective Tax Rate	~11.0% - 12.0%		~13.0%
Adjusted Diluted Weighted Average Shares	~239M		~236M

https://finance.yahoo.com/news/endo-reports-third-quarter-2021-201500240.html